Mabylon AG raises CHF 30 million for allergy therapy

Fungal-Driven Airways Dis-Immunity From Asthma to Allergic Bronchopulmonary Aspergillosis: Dissecting Similarities and Differences. Marco Caminati Read the article here: doi.org/10.1111/all.16687 Allergic bronchopulmonary aspergillosis (ABPA) is easily misdiagnosed as asthma due to its similar clinical manifestations. With 119 references, this is a review article written by the European Academy of Allergy and Clinical Immunology (#EAACI) Task Force on the diagnosis and therapeutic management of ABPA. It includes a discussion on the role of epithelial barrier dysfunction in their pathological mechanisms, clinical hallmarks, biomarkers, molecular diagnosis, pediatric perspective, and targeted therapies. Read more articles published in #Allergy on #asthma here: https://lnkd.in/dvHaYziZ #allergy_journal

Early findings from the University of Pennsylvania Perelman School of Medicine and Cincinnati Children's suggest a new vaccine may prevent allergens from triggering harmful immune reactions and inflammation. The vaccine, outlined in the Journal of Clinical Investigation, may one day be tested and tailored to a variety of seasonal and food allergies. “This is a potential breakthrough for millions of people worldwide who suffer from life-threatening allergies,” said Nobel laureate Drew Weissman, MD, PhD, the Roberts Family Professor in Vaccine Research at Penn and co-lead of the study. In collaboration with Penn colleagues, Jilian Melamed, PhD, an assistant professor of Infectious Diseases, Mohamad-Gabriel Alameh, PhD, an assistant professor of Pathology and Laboratory Medicine, and the Cincinnati Children’s researchers led by Marc E. Rothenberg, MD, PhD, director of the division of Allergy and Immunology, modeled this new vaccine on the design of the COVID-19 mRNA lipid nanoparticle (LNP) vaccines. Learn more: https://lnkd.in/gfCj6FJ7

Hypersensitivity Reactions – Overview👇 ✅Hypersensitivity reactions are exaggerated or inappropriate immune responses to antigens (allergens) that cause tissue damage or disease. These reactions are classified into four main types based on the mechanism and timing of the response. ✅Type I (Immediate / Anaphylactic): This reaction occurs within minutes of exposure to an allergen. It is mediated by IgE antibodies that trigger mast cells and basophils to release histamine and other chemicals. Common examples include asthma, hay fever, and anaphylaxis. ✅Type II (Cytotoxic): Here, IgG or IgM antibodies target antigens on cell surfaces, leading to cell destruction through complement activation or phagocytosis. Examples include hemolytic anemia, blood transfusion reactions, and some autoimmune disorders. ✅Type III (Immune Complex-Mediated): This involves antigen-antibody (IgG) complexes that deposit in tissues, causing inflammation and tissue damage. It’s seen in conditions like systemic lupus erythematosus (SLE) and serum sickness. ✅Type IV (Delayed-Type / Cell-Mediated): This reaction is mediated by T-cells, not antibodies, and typically appears 48–72 hours after exposure. It includes contact dermatitis, tuberculin skin test reactions, and graft-versus-host disease. ✅Clinical Relevance: Identifying the type of hypersensitivity is crucial for diagnosis and management, especially in allergies, autoimmune diseases, and during drug therapy. #HypersensitivityReactions #Immunology #Type1to4 #Allergy #AutoimmuneDiseases #MedicalEducation #ImmuneResponse #Anaphylaxis #ClinicalImmunology

✨One of the most appreciated/liked articles in the social media of Allergy published in 2025: Open Access: Endotypes in Immune-Mediated Drug Reactions: Present and Future of Relevant Biomarkers. An EAACI Task Force Report. Corresponding author: Cristobalina Mayorga Read the article here: doi.org/10.1111/all.16576 This is a Position Paper written by the European Academy of Allergy and Clinical Immunology (#EAACI) on the biomarkers available for the diagnosis of drug-induced immune reactions. It includes a discussion on the definition and characteristics of #biomarkers, mechanisms and biomarkers in immediate-drug hypersensitivity reactions (IDHRs) induced by antigenic-immune response and nonspecific activation of the immune system, mechanisms and biomarkers in delayed-DHRs (DDHRs), molecular mechanisms of viral infections in DHRs, and future directions. Read more articles published in #Allergy on drug-induced immune reactions here: https://lnkd.in/gfs_z4g6 #Allergy_journal

📃 Allergen immunotherapy: effective on lung function?  📕 Current Opinion in Allergy and Clinical Immunology 🖇️ https://lnkd.in/dbYRa5Vt Edoardo Cavaglià, Maurizio Marogna, Giovanni Paoletti, Giorgio Walter Canonica and Enrico Heffler This new review highlights the real power of allergen immunotherapy in asthma care . Even though much research focuses on reducing symptoms 🤧 and medication 💊, we now see signs it could help protect lung function for years 🫁⏳. The most interesting long-term results come from Marogna’s 15-year observational study 📊. People who had sublingual immunotherapy kept better lung function compared to those who only used standard asthma treatment 💭. This opens a door 🚪: with more modern and published trials 📖🔬, allergen immunotherapy could bring long-term health 🌿🌟 beyond everyday asthma control.

Hypersensitivity Reactions 🌷 Why We Get Allergies Our immune system is built to protect us — but sometimes, it overshoots and causes harm. These hypersensitivity reactions are classified into four main types (I–IV), each with distinct mechanisms and clinical outcomes: 🌸 Type I – Immediate (Allergic) Reactions Driven by IgE and mast cells reacting to soluble antigens. Examples: Allergic rhinitis, asthma, systemic anaphylaxis. 🩸 Type II – Antibody-Mediated Cytotoxicity Mediated by IgG antibodies against cell- or matrix-associated antigens, leading to complement activation and phagocytosis. Examples: Hemolytic anemia, thrombocytopenia. ⚖️ Type III – Immune Complex-Mediated Immune complexes deposit in tissues, activating complement and inflammatory cells. Examples: Serum sickness, Arthus reaction. 🔥 Type IV – T-cell Mediated (Delayed-Type) Orchestrated by T-cells (Th1, Th2, CTLs, etc.) through cytokine release or direct cytotoxicity. Examples: Tuberculin reaction, chronic asthma, contact dermatitis, Behçet’s disease. Recognizing the underlying mechanism of hypersensitivity reactions helps clinicians and researchers tailor treatment strategies — whether it’s antihistamines for Type I allergies, immunosuppressants for T-cell–mediated reactions, or biologics targeting cytokine pathways. Credit to DiPiro JT, Talbert RL, et. al. for the great image! #Immunology #Science #Allergies

Allergy and immunology are specialised fields of medicine that address the diagnosis, management, and prevention of immune-related disorders. The QualCert Level 7 Postgraduate Diploma in Allergy and Immunology (PgDAI) is designed for healthcare professionals seeking advanced expertise in immunopathology, clinical allergy management, and evidence-based practice. This qualification equips learners with the knowledge and skills required to deliver specialist care, conduct research, and contribute to the advancement of immunological healthcare services. The PgDAI programme provides a comprehensive study of the immune system, including the pathophysiology of allergic and autoimmune disorders, immunodeficiency, and hypersensitivity reactions. Learners explore diagnostic approaches, therapeutic interventions, and emerging treatments within the context of clinical practice. The course combines theoretical knowledge with practical applications, enabling participants to manage complex immunological cases with confidence and precision. The PgDAI equips professionals with specialist skills to manage a wide range of immune-related conditions, from common allergies to complex immunodeficiency disorders. Learners gain the ability to apply advanced diagnostic techniques, design patient-centred care plans, and integrate public health strategies into practice. Graduates are prepared to take on clinical, research, and leadership roles within healthcare institutions, research organisations, and public health services. Completing the PgDAI opens pathways to advanced clinical practice, specialist roles in immunology clinics, hospital settings, and research institutions. Graduates may also pursue leadership positions, contribute to policy development, or engage in doctoral-level research in immunology, allergy, and related medical fields. https://lnkd.in/ewdtvPMN QualCert UK Ltd #qualcert #qualcertuk #qualcertawardingbody #becomeatc #Level7PostgraduateDiploma #PgDAI #AllergyAndImmunology #Immunology #AllergyStudies #MedicalDiploma #HealthcareEducation #award #certificate #diploma #training #education #AdvancedPrinciplesOfImmunologyAndImmuneSystemFunction #ClinicalAssessmentAndDiagnosticTechniquesInAllergyAndImmunology #ManagementOfAllergicAndAutoimmuneDisorders

https://lnkd.in/gYkQQHgB #breastcancer #cancerresearch #oncology #cancertreatment #immunology #immunotherapy Allergy drug turns T cells against cancer A common #allergy #medication could help the immune system fight an aggressive form of breast cancer. The allergy medication cromolyn and an immunotherapy drug worked together to shrink tumours in 5 out of 10 people with advanced triple-negative breast cancer. Cromolyn increased the presentation of tumour antigens by mast cells, making T cells more likely to target and kill cancer cells. People with higher levels of antigen-presenting mast cells were more responsive to immunotherapy and had a better prognosis. Mast cells are a diverse group of cells that typically help the body respond to parasites and allergies.

Appili Therapeutics is excited to announce that the National Institute of Allergy and Infectious Diseases (NIAID) will provide up to US$40 million to accelerate development of VXV-01—a breakthrough vaccine targeting invasive fungal infections, in partnership with Vitalex Bioscience. This funding will advance VXV-01 through manufacturing, nonclinical studies, clinical and regulatory activities. Together, Appili and Vitalex are dedicated to delivering vital solutions for millions affected by these life-threatening infections. Appili leverages proven expertise in vaccine innovation and government partnerships to drive VXV-01 forward and enhance global health. $APLI $APLIF Read the full announcement: https://lnkd.in/gp-6qAPc

📌 What is Pneumococcal 20 (PCV20)? Pneumococcal 20-valent conjugate vaccine (PCV20) is a pneumococcal conjugate vaccine that protects against 20 different serotypes of Streptococcus pneumoniae, a bacterium responsible for diseases such as pneumonia, meningitis, bacteremia, and otitis media. It is the most broad-spectrum pneumococcal conjugate vaccine available, expanding coverage beyond PCV13 by including 7 additional serotypes. ⸻ 📌 Composition & Coverage PCV20 contains polysaccharides from 20 pneumococcal serotypes conjugated to a diphtheria-derived carrier protein (CRM197), which enhances immune response. • Serotypes covered: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F ⸻ 📌 Indications • Infants & children (6 weeks–17 years) – for prevention of invasive pneumococcal disease and otitis media. • Adults (≥18 years) – for prevention of pneumococcal pneumonia, bacteremia, and meningitis. • Particularly recommended for: • Adults ≥65 years • Immunocompromised patients • Chronic disease patients (heart, lung, liver, diabetes, kidney disease) • Smokers ⸻ 📌 Dosage & Administration • Route: Intramuscular (IM) injection, usually in the thigh (infants) or deltoid muscle (children & adults). • Schedule: • Infants: 3 primary doses + 1 booster (at 2, 4, 6, and 12–15 months) • Adults: Single dose (if not previously vaccinated with other PCV) ⸻ 📌 Mechanism of Action • The conjugated polysaccharides stimulate the immune system to produce serotype-specific antibodies. • Provides both humoral and cellular immunity, giving long-lasting protection and reducing nasopharyngeal carriage, which helps in herd immunity. ⸻ 📌 Side Effects Generally mild and temporary: • Local: pain, redness, swelling at injection site • Systemic: fever, irritability, fatigue, headache, muscle pain • Rare: allergic reaction, anaphylaxis ⸻ 📌 Advantages of PCV20 • Broadest coverage (20 serotypes vs. 13 in PCV13 and 15 in PCV15) • Reduces invasive pneumococcal disease (IPD) burden significantly • Simplifies vaccination schedule (adults can often complete with a single PCV20 dose, no need for additional PPSV23 in many cases) ⸻ 📌 Clinical Pharmacist’s Role in PCV20 • Patient education: importance of vaccination, adherence to schedule • Vaccine administration: counseling and safe injection technique • Monitoring: observing for adverse reactions, documenting in records • Immunization program support: ensuring high-risk groups get coverage • Collaboration: working with physicians to avoid duplication with other pneumococcal vaccines (PCV13, PCV15, PPSV23) ⸻ 📌 Key Takeaway Pneumococcal 20-valent conjugate vaccine (PCV20) is a powerful tool in preventing pneumococcal infections across all age groups. Its broad protection, ease of use, and safety profile make it a cornerstone in modern vaccination programs.